{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:28:47Z","timestamp":1789954127418,"version":"4.0.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.jhep.2016.06.019","type":"journal-article","created":{"date-parts":[[2016,7,4]],"date-time":"2016-07-04T22:47:04Z","timestamp":1467672424000},"page":"741-747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":351,"title":["Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis"],"prefix":"10.1016","volume":"65","author":[{"given":"Michelle C.M.","family":"Cheung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex J.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin E.","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McLauchlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Mutimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William T.H.","family":"Gelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas C.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham R.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Irving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2016.06.019_b0005","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.06.019_b0010","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.06.019_b0015","series-title":"Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV infection and decompensated cirrhosis: interim analysis of a French multicentre compassionate use programme European association for the study of the liver","author":"Leroy","year":"2016"},{"key":"10.1016\/j.jhep.2016.06.019_b0020","series-title":"Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV infection in patients with decompensated cirrhosis: results of a European Multicentre Compassionate Use Programme. European Association for the Study of the Liver","author":"Petersen","year":"2016"},{"key":"10.1016\/j.jhep.2016.06.019_b0025","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution","volume":"65","author":"Reig","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.06.019_b0030","series-title":"Development of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. European Association for the Study of the Liver","author":"Buonfiglioli","year":"2016"},{"key":"10.1016\/j.jhep.2016.06.019_b0035","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/gast.2002.33023","article-title":"Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C","volume":"122","author":"Poynard","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.06.019_b0040","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2016.06.019_b0045","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-142-2-200501180-00009","article-title":"Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival","volume":"142","author":"Shiratori","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2016.06.019_b0050","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hep.21492","article-title":"Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study","volume":"45","author":"Bruno","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.06.019_b0055","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"Liver EAfSo. EASL recommendations on treatment of hepatitis C 2015","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.06.019_b0060","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.06.019_b0065","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/jvh.12534","article-title":"Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? The ironic conundrum in the era of effective and well-tolerated therapy","volume":"23","author":"Bunchorntavakul","year":"2016","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2016.06.019_b0070","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.06.019_b0075","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1053\/j.gastro.2010.11.050","article-title":"Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C","volume":"140","author":"Lok","year":"2011","journal-title":"Gastroenterology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816303142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816303142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T11:22:22Z","timestamp":1668597742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827816303142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0168827816303142"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2016.06.019","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726490007.793520767","asserted-by":"object"}]},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2016.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}